Form 6-K NOVO NORDISK A S For: Sep 20
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
TD Cowen Reiterates Buy Rating on Novo Nordisk (NVO) Following Monlunabant Obesity Update
September 20, 2024 10:12 AM EDTTD Cowen analyst Michael Nedelcovych reiterated a Buy rating and $155.00 price target on Novo Nordisk (NYSE: NVO) following the monlunabant obesity update.
The analyst commented, "In a Phase II obesity trial, CB1 blocker monlunabant showed weight loss in the ~6-7% range at 16 weeks. No serious... More
